Aptevo Therapeutics Operating Income 2014-2022 | APVO
Aptevo Therapeutics operating income from 2014 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Aptevo Therapeutics Annual Operating Income
(Millions of US $) |
| 2021 |
$-21 |
| 2020 |
$-27 |
| 2019 |
$-41 |
| 2018 |
$-52 |
| 2017 |
$-54 |
| 2016 |
$-139 |
| 2015 |
$-61 |
| 2014 |
$-51 |
| 2013 |
$ |
Aptevo Therapeutics Quarterly Operating Income
(Millions of US $) |
| 2022-03-31 |
$-6 |
| 2021-12-31 |
$-4 |
| 2021-09-30 |
$-5 |
| 2021-06-30 |
$-6 |
| 2021-03-31 |
$-7 |
| 2020-12-31 |
$-7 |
| 2020-09-30 |
$-6 |
| 2020-06-30 |
$-7 |
| 2020-03-31 |
$-8 |
| 2019-12-31 |
$-8 |
| 2019-09-30 |
$-11 |
| 2019-06-30 |
$-10 |
| 2019-03-31 |
$-11 |
| 2018-12-31 |
$-14 |
| 2018-09-30 |
$-12 |
| 2018-06-30 |
$-12 |
| 2018-03-31 |
$-14 |
| 2017-12-31 |
$-17 |
| 2017-09-30 |
$-10 |
| 2017-06-30 |
$-15 |
| 2017-03-31 |
$-12 |
| 2016-12-31 |
$-22 |
| 2016-09-30 |
$-91 |
| 2016-06-30 |
$-13 |
| 2016-03-31 |
$-13 |
| 2015-12-31 |
|
| 2015-09-30 |
$-13 |
| 2015-06-30 |
$-18 |
| 2014-12-31 |
|
| 2013-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.018B |
$0.012B |
|
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
|
